An in-vitro Elucidation of Inhibitory Potential of Carminic Acid: Possible Therapeutic Approach for Neurodegenerative Diseases
Aggregation, Carminic acid, Inhibition, Human serum albumin, Neurodegenerative diseases
Digital Object Identifier (DOI)
Protein misfolding leads to several human pathologies. So far, there has not been much success on the remediations of these protein conformational disorders. Since these diseases arise as a result of protein aggregation, hence inhibition of aggregation could be a promising approach for designing new therapeutics. For which; polyphenols, antibiotics and other small compounds have been tested by the researchers in the recent past, but so far there has not been much success. Here we have investigated the effect of carminic acid over Human serum albumin in an in vitro manner. It was observed that there was severe resistance in the increment of fluorescence intensity in the presence of carminic acid when observed through ANS, ThT and RLS, which was further supported by CD and Congo red assay. Microscopic analysis also confirmed that there was aggregation inhibition in the presence of180μM carminic acid. ROS and SDS-PAGE results also established the same. Furthermore, molecular docking was performed to understand the interacting residues which were found to be Arg, Leu, Glu. It is noteworthy that inhibitory effect was concentration dependent and maximum inhibition was found to be in presence of 180 μM of carminic acid. These results shall be helpful in designing the new therapeutics against amyloidosis.
Was this content written or created while at USF?
Citation / Publisher Attribution
Journal of Molecular Liquids, v. 303, art. 112692
Scholar Commons Citation
Zakariya, Syed Mohammad; Furkan, Mohammad; Zaman, Masihuz; Chandel, Tajalli Ilm; Ali, Syed Moasfar; Uversky, Vladimir N.; and Khan, Rizwan Hasan, "An in-vitro Elucidation of Inhibitory Potential of Carminic Acid: Possible Therapeutic Approach for Neurodegenerative Diseases" (2020). Molecular Medicine Faculty Publications. 197.